Does Rallies show Form 4 insider transactions for HYPR?

Yes. Rallies tracks HYPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HYPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HYPR. It does not provide personalized investment advice.

HYPR (Hyperfine, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Hyperfine, Inc. Class A Common Stock (HYPR) is a publicly traded Healthcare sector company. As of May 21, 2026, HYPR trades at $1.49 with a market cap of $143.94M and a P/E ratio of -3.66. HYPR moved +5.67% today. Year to date, HYPR is +49.49%; over the trailing twelve months it is +137.83%. Its 52-week range spans $0.53 to $2.22. Analyst consensus is strong buy with an average price target of $2.17. Rallies surfaces HYPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HYPR stock inside the company?

Recent HYPR insider activity includes TEISSEYRE THOMAS sold 24.19K, HALE BRETT sold 24.19K, TEISSEYRE THOMAS sold 821, TEISSEYRE THOMAS sold 1.41K, and TEISSEYRE THOMAS sold 1.15K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HYPR Key Metrics

Key financial metrics for HYPR
Metric	Value
Price	$1.49
Market Cap	$143.94M
P/E Ratio	-3.66
EPS	$-0.40
Dividend Yield	0.00%
52-Week High	$2.22
52-Week Low	$0.53
Volume	50
Avg Volume	0
Revenue (TTM)	$15.33M
Net Income	$-34.78M
Gross Margin	51.20%

Recent HYPR Insider Trades

TEISSEYRE THOMAS sold 24.19K (~$29.27K) on Mar 23, 2026.
HALE BRETT sold 24.19K (~$29.27K) on Mar 23, 2026.
TEISSEYRE THOMAS sold 821 (~$912.541) on Feb 13, 2026.
TEISSEYRE THOMAS sold 1.41K (~$1.52K) on Nov 19, 2025.
TEISSEYRE THOMAS sold 1.15K (~$1.53K) on Aug 18, 2025.

Latest HYPR News

Hyperfine Benefits as FDA Registry Tops 1,200 AI Devices, Spurring Funding Surge — Mar 27, 2026
Hyperfine Raises Price to $590K, Reports Record Q4 Growth and India Approval — Mar 19, 2026
Hyperfine Q4 2025 Forecast at $5.16M Revenue, Price Target Implies 39% Upside — Mar 17, 2026
Hyperfine enrolls first patient in contrast MRI trial, eyes $70.92B point-of-care market — Jan 16, 2026
Hyperfine Enrolls First Patient in Swoop Portable MRI Contrast Agent Feasibility Study — Jan 16, 2026

HYPR Analyst Consensus

3 analysts cover HYPR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.17.

Common questions about HYPR

Who is trading HYPR stock inside the company?: Recent HYPR insider activity includes TEISSEYRE THOMAS sold 24.19K, HALE BRETT sold 24.19K, TEISSEYRE THOMAS sold 821, TEISSEYRE THOMAS sold 1.41K, and TEISSEYRE THOMAS sold 1.15K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HYPR?: Yes. Rallies tracks HYPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HYPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HYPR. It does not provide personalized investment advice.